مباشر

FierceBiotechMadrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J Endpoints NewsSwiss manufacturing, biotech industry so far unfazed by geopolitics Endpoints NewsPfizer ends Trillium-related development as R&D spend jumps Endpoints NewsMicrobiome startup raises $48M for immunotherapy and malnutrition treatments Endpoints NewsJ&J's IBD combo fails Phase 2 studies, but will move into pivotal testing FierceBiotechPfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager FierceBiotechSanofi expands AI capabilities, investing $294M to scale Toronto hub Endpoints NewsMadrigal extends MASH deal streak with Arrowhead drug that J&J didn't want Endpoints NewsHealthcare organizations are increasingly building their own AI tools PharmaVoiceWhat’s at stake in Amgen’s showdown with the FDA?Promega BlogBeyond the Liver: How Liposomal LNPs Are Expanding the Reach of mRNA Delivery BioPharma DiveVertex earnings get muted investor response

Endpoints News ٥ مايو ٢٠٢٦

Cytokinetics succeeds where Bristol Myers failed in heart muscle disease

Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial...

Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The company said Tuesday that Myqorzo ...